FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents

Particulate Form (e.g., Powders, Granules, Beads, Microcapsules, And Pellets)

Particulate Form (e.g., Powders, Granules, Beads, Microcapsules, And Pellets) patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

Related Categories:

Drug, Bio-affecting And Body Treating Compositions


Preparations Characterized By Special Physical Form > Particulate Form (e.g., Powders, Granules, Beads, Microcapsules, And Pellets)



Electrophoretically deposited strontium fluoride nanoparticle/polymer coatings for medical implants
02/26/15 - 20150056282 - The present disclosure provides for co-electrophoretic deposition (co-EPD) of organo-functionalized strontium fluoride nanoparticles (SrF2) with a hydrophobic polymer in the presence of non-aqueous aprotic solvents. The co-EPD procedure can be employed to form a coating or self-supporting film for application to a metal implant....

Methods of using cerium oxide nanoparticles to mitigate or protect against radiation injury
02/26/15 - 20150056283 - Methods of mitigating the effects of radiation exposure or providing a radioprotective effect in a subject are provided herein. The methods include administering a therapeutically effective amount of cerium oxide nanoparticles to the subject to mitigate the effects of radiation exposure or to offer a radioprotective effect to the subject....

Pharmaceutical composition
02/26/15 - 20150056284 - A preparation for oral administration comprising: a pregelatinized starch comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboxyimide hydrochloride (lurasidone) represented by the formula (1) as an active ingredient; a water-soluble excipient; and a water-soluble polymeric binder, the preparation exhibiting an invariant level of elution behavior even when the content of its active ingredient is varied....

Sustained release formulations using non-aqueous carriers
02/26/15 - 20150056285 - The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer...

Nanoparticulate megestrol formulations
02/26/15 - 20150056286 - The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm....

Nanoparticulate megestrol formulations
02/26/15 - 20150056287 - The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm....

Compositions for treatment of skin disorders
02/19/15 - 20150050342 - Compositions are provided comprising: (i) chlorhexidine or a pharmaceutically acceptable salt thereof; (ii) niacinamide or niacin; and (iii) salicylic acid or a pharmaceutically acceptable salt or derivative thereof. The compositions are suitable for use in treating and preventing disorders of the skin. The compositions are also provided in the form...

Methods of wound care and treatment
02/19/15 - 20150050343 - Provided are electrokinetically-altered fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating a wound to a surface...

Compositions and methods for upregulating hippocampal plasticity and hippocampus-dependent learning and memory
02/19/15 - 20150050344 - Provided are methods for enhancing hippocampal plasticity and hippocampal-mediated learning and memory, and/or enhancing the synaptic maturation of neurons, and/or optimizing or enhancing neuronal synaptic transmission, and/or enhancing intracellular oxygen delivery or utilization, and/or enhancing ATP synthesis, comprising administration, to a subject in need thereof of a sufficient amount over...

Methods for fine particle manufacture
02/19/15 - 20150050345 - Processes for preparing micronized particles comprising a poorly water soluble bioactive agent are provided. The processes utilize a superheated aqueous phase which can serve as the continuous phase of an emulsion. The superheated aqueous phase can be used to melt poorly water soluble bioactive agents and/or matrix materials which them...

Compositions and methods for treating insulin resistance and diabetes mellitus
02/19/15 - 20150050346 - Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders...

Reverse micelle system comprising nucleic acids and use thereof
02/19/15 - 20150050347 - The present invention relates to reverse micelle system based on sterols, acylglycerols, phospholipids or sphingolipids and nucleic acids. The reverse micelle system of the invention is able to cross mucosa and cellular membranes. It thus allows vectorization of nucleic acids to target sites. It is advantageously useful in the pharmaceutical...

Aerosol tyrosine kinase inhibitor compounds and uses thereof
02/12/15 - 20150044288 - Disclosed herein are formulations of imatinib or a phenylaminopyrimidine derivative compound for aerosolization and use of such formulations for inhaled aerosol administration of imatinib or a phenylaminopyrimidine derivative compound for the prevention or treatment of various fibrotic, carcinogenic, vascular and viral infectious diseases, including diseases associated with the lung, heart,...

Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate
02/12/15 - 20150044289 - Provided are hypromellose acetate succinates (HPMCAS) for use as a hot-melt extrusion carrier having a volume average particle size (D50) of from 70 to 300 as measured by dry laser diffraction and a loose bulk density of from 0.25 to 0.40 g/cm3; and a hot-melt extrusion composition comprising the HPMCAS...

Treatment method using liquid food composition
02/12/15 - 20150044290 - Provided is a liquid food composition capable of semi-solidifying in the stomach, which is a one-pack type product containing a water-soluble dietary fiber preliminarily added thereto and in the form of a liquid that can be easily taken, and stably sustains the liquid nature thereof during distribution and storage. The...

Methods for the treatment of endometriosis
02/12/15 - 20150044291 - Endometriosis, including endometriosis externa, endometrioma, adenomyosis, adenomyomas, adenomyotic nodules of the uterosacral ligaments, and endometriotic nodules, such as scar endometriosis are effectively treated by the intralesional administration, including transvaginal, endoscopic or open surgical administration including via laparotomy, of a progestogen. Compositions therefor also are provided....

Cosmetic composition
02/05/15 - 20150037418 - and wherein, a mass ratio of the component (A) to the component (D), (A)/(D), is from 0.1 to 100....

Functional pla-peg copolymers, the nanoparticles thereof, their preparation and use for targeted drug delivery and imaging
02/05/15 - 20150037419 - Functional PLA-PEG copolymers, the nanoparticles thereof, their preparation and use for targeted drug delivery and imaging The present invention concerns novel functional PEG-PLA containing copolymers, the nanoparticles containing the same, their process of preparation and their use for site specific targeted drug delivery and imaging....

Methods and compositions for treating wounds and reducing the risk of incisional hernias
01/29/15 - 20150030678 - Provided are methods and compositions for treating a wound in a subject. The methods include applying a pharmaceutical composition that includes a first precursor material agent including fibrinogen, a second precursor material agent including thrombin, and silver particles to an abdominal incision site in an amount effective to treat the...

Dry powder formulations of dnase i
01/22/15 - 20150024050 - DNase I formulations for pulmonary administration and, more particularly, but not exclusively, a dry powder formulation comprising, as an active ingredient, human DNase I, methods, dry powder inhalation devices and systems for the therapeutic use thereof are provided....

Injectable hydrogel system to modulate host response at bone implant interface
01/22/15 - 20150024051 - A bone implant primer is provided. A biodegradable hydrogel component is provided. A plurality of biomolecule release depots are dispersed within the biodegradable hydrogel component wherein the plurality of biomolecule release depots comprise biomolecules for aiding implant osseointegration or biomolecules for mitigation of foreign body response. Different biomolecules may be...

Nitric oxide releasing pharmaceutical compositions
01/22/15 - 20150024052 - The present invention generally relates to nitric oxide releasing pharmaceutical compositions and methods of using the same....

Topical wound treatment method and composition
01/22/15 - 20150024053 - A topical wound treatment composition comprises a hydrogen peroxide generator; alkaline powder; not more than 5 percent by weight of water; additional topical active agent if desired, and emollient (preferably hygroscopic emollient) to balance. When topically applied to a wound and water from the surrounding environment diffuses into the composition,...

Solid pharmaceutical dispersions with enhanced bioavailability
01/22/15 - 20150024054 - Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or bioavailability in a use environment....

Enhanced immediate release formulations of topiramate
01/22/15 - 20150024055 - The present invention provides enhanced immediate release formulations of topiramate, in which 80% of the active ingredient is released in the period of time of not more than 30 min. These formulations may be advantageously used for the treatment of acute neurological conditions, such as migraine....

Controlled release sterile injectable aripiprazole formulation and method
01/22/15 - 20150024056 - A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle thereof, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A...

Dry powder formulation of azole derivative for inhalation
01/15/15 - 20150017244 - A spray dried-powder composition for inhalation comprising particles (X) containing (a) between 5 and 50% by weight of at least one azole derivative in amorphous state but not in crystalline structure and (b) at least one matricial agent to the composition selected from a group consisting of polyol such as...

Methods of treating cancers with therapeutic nanoparticles
01/15/15 - 20150017245 - The present disclosure relates in part to methods of treating cholangiocarcinoma or tonsillar cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a nanoparticle composition, wherein nanoparticle composition comprises nanoparticles....

Immune-modifying nanoparticles for the treatment of inflammatory diseases
01/08/15 - 20150010631 - The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles....

Novel aerosol formulations of granisetron and uses thereof
01/08/15 - 20150010632 - Aerosol formulations of granisetron useful for pulmonary delivery are provided. The formulations are useful in the reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative...

Novel aerosol formulations of ondansetron and uses thereof
01/08/15 - 20150010633 - Aerosol formulations of ondansetron useful for pulmonary delivery are provided. The formulations are useful in the reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative...

Prevention and treatment of ocular conditions
01/08/15 - 20150010634 - The present invention relates to pharmaceutical compositions comprising hydrogel-linked prodrug for use in the treatment, prevention and/or diagnosis a condition of the eye and ophthalmic devices comprising said pharmaceutical compositions....

Controlled release particles, wood treatment agent, and producing method thereof
01/08/15 - 20150010635 - Controlled release particles are obtained by dissolving a hydrophobic antibiotic compound with a hydrophobic polymerizable vinyl monomer to prepare a hydrophobic solution, blending water with an emulsifier to prepare an aqueous emulsifier solution, emulsifying the hydrophobic solution in the aqueous emulsifier solution, and polymerizing the polymerizable vinyl monomer by mini-emulsion...

Apparatus and method for reducing the occurrence of post-surgical adhesions
01/08/15 - 20150010636 - A method for inhibiting formation of adhesions following abdominal surgery which involves application of an anti-static fatty acid ethoxylated amide (Cocamide DEA) in a matrix that is placed in the peritoneal cavity at the conclusion of an abdominal surgery and which releases this anti-adhesive chemical over a predetermined time in...

Aqueous suspensions of tmc278
01/08/15 - 20150010637 - This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the NNRTI compound TMC278, suspended in an aqueous pharmaceutically acceptable carrier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of HIV infection....

Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
01/01/15 - 20150004232 - Dermal delivery compositions are provided. Aspects of the dermal delivery compositions include the presence of active agent-calcium phosphate particle complexes, where these complexes include uniform, rigid, spherical nanoporous calcium phosphate particles associated with one or more active agents. Also provided are methods of using the compositions in active agent delivery...

Respirably dry powder comprising calcium lactate, sodium chloride and leucine
01/01/15 - 20150004233 - The present invention relates to respirable dry powders that contain respirable dry particles that comprise about 20%-37.5% (w/w) leucine, about 58.6-about 75% (w/w) calcium lactate, and about 3.9-about 5% (w/w) sodium chloride, and methods for treating a subject using the respirable dry powders....

Nanoparticulate compositions and formulations of piperazine compounds
01/01/15 - 20150004234 - The present invention relates to storage stable nanoparticulate compositions of piperazine compounds. The pharmaceutical compositions comprising the nanoparticulate compositions that are useful for the treatment and prevention of proliferative diseases including cancer are also described....

Microporous zirconium silicate for the treatment of hyperkalemia
01/01/15 - 20150004235 - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of...

Efficient process for the preparation of lycopene containing oleoresin and lycopene crystals for human consumption
01/01/15 - 20150004236 - The present invention provides a process for the preparation of lycopene containing oleoresin and lycopene crystals for human consumption. The present invention provides an efficient process for the preparation of lycopene crystals from lycopene containing oleoresin with at least 85% by weight lycopene, containing at least 90% by weight trans-lycopene...

Cellulose derivatives for inhibiting crystallization of poorly water-soluble drugs
01/01/15 - 20150004237 - is 3, 4, 6, or 8 to provide a ω-carboxyalkanoyl group chosen from succinoyl, glutaroyl, adipoyl, sebacyl, and suberyl groups; and wherein R is chosen from: a hydrogen atom; and an alkanoyl group chosen from acetyl, propionyl, butyryl, valeroyl, hexanoyl, nonanoyl, decanoyl, lauroyl, palmitoyl, and stearoyl groups; wherein there is...

Emulsions providing stable vitamin compositions and methods of forming compositions thereof
01/01/15 - 20150004238 - Stable vitamin oil-in-water emulsions and methods of making those emulsions are described herein. The emulsions may be used to make beverage products that include fat-soluble vitamins. The emulsions may also be used in beverage products that are colored and which maintain color stability for an extended period of time....

Levofloxacin inhalation composition
12/25/14 - 20140377355 - An antibiotic inhalation composition for the treatment of bacteria related diseases in the respiratory tract is provided. The antibiotic inhalation composition may include a mixture of levofloxacin and a micronized poloxamer composition (excipient/solubilizer). Micronized poloxamer composition may include poloxamer 188 and poloxamer 407. The manufacturing method for micronized poloxamer composition...

Inhalation composition for treating respiratory tract infections
12/25/14 - 20140377356 - An inhalation composition for the treatment of bacteria related diseases in the respiratory tract is provided. The inhalation composition may include a mixture of levofloxacin, betamethasone, and a micronized poloxamer composition (excipient/solubilizer). Micronized poloxamer composition may include poloxamer 188 and poloxamer 407. The manufacturing method for micronized poloxamer composition may...

Poloxamer based inhalation composition
12/25/14 - 20140377357 - An inhalation composition for the treatment of bacteria related diseases is provided. The disclosed composition may include a mixture of three or more API(s) and a micronized poloxamer composition. Micronized poloxamer composition may include poloxamer 188 and poloxamer 407. According to an embodiment, an inhalation composition including one or more...

Nanoparticulate formulation comprising a trpa1 antagonist
12/25/14 - 20140377358 - The present invention relates to a nanoparticulate formulation comprising a transient receptor potential ankyrin-1 receptor (“TRPA1”) antagonist. Particularly, the present invention relates to a nanoparticulate formulation comprising a thienopyrimidinedione derivative as a TRPA1 antagonist and a surface stabilizer; a process for preparing such formulation; and its use in treating a...

Microporous zirconium silicate for the treatment of hyperkalemia
12/25/14 - 20140377359 - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of...

Composition for controlled release of physiologically active substance
12/25/14 - 20140377360 - A composition for controlled release of a physiologically active substance can release a physiologically active substance in vivo at the desired timing. The composition includes an inner layer that is formed of a biodegradable substance that supports a physiologically active substance, and an outer layer that is formed of a...

Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
12/25/14 - 20140377361 - A microparticle for drug delivery comprises an active agent and an excipient, the excipient comprising a metal ion-lipid complex. The metal ion is chosen from the group consisting of lanthanide metals, actinide metals, group IIa and IIIb metals, transition metals or mixtures thereof. The lipid comprises a phospholipid. The complex...

Hemostatic compositions, devices, and methods
12/25/14 - 20140377362 - Compositions that include a clay such as kaolin dispersed in a liquid such as water may be useful for promoting the clotting of blood. The compositions may be in a liquid, gel, paste, foam, or another form. Uses may include treating a traumatic injury such as in injury caused by...

1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
12/25/14 - 20140377363 - This disclosure relates to a method of treating a disease selected from the group consisting of affective disorders, depression, major depressive disorder, anxiety, general anxiety disorder, social anxiety disorder, obsessive compulsive disorder, panic disorder, and panic attacks. The method includes administering a therapeutically effective amount of Compound I or a...

Weight loss compositions and methods for appetite suppression
12/18/14 - 20140370095 - A beverage composition for weight loss is provided which includes cayenne pepper; a palate enhancing agent selected from the group consisting of fruits, herbs, vegetables and mixtures thereof, the agent including pulp of the fruits, the herbs, the vegetables or the mixtures thereof; a least two spices selected from the...

Gas transporting rheological medium, end uses and related apparatus-method
12/18/14 - 20140370096 - A two-phase mixture is provided having a dissolved gas and a suspension of bubbles in a liquid. Methods for making, maintaining, and using the two-phase mixture are also provided. The gas molecules may be introduced into the liquid at a high velocity under elevated pressure to form a supersaturated solution...

Sterile pharmaceutical compositions
12/18/14 - 20140370097 - The present invention provides a method for the sterilization of a labile glucocorticosteroid, which method comprises heat-treating by moist heat the labile glucocorticosteroid in the form of a suspension for a sterilizing-effective time. The methods and compositions according to the invention are useful as therapeutic tools to prevent, reverse, and/or...

Tinted emulsion
12/18/14 - 20140370098 - The present invention relates to a cosmetic composition for caring for and/or making up keratin materials which is in the form of an oil-in-water emulsion which undergoes phase inversion when it is applied to said keratin materials, comprising: (i) at least one pigment having a particle size greater than 100...

Artificial antigen presenting cells having a defined and dynamic shape
12/18/14 - 20140370099 - Compositions and methods comprising asymmetrical artificial antigen presenting cells (aAPCs) are disclosed. The non-spherical aAPCs more closely mimic endogenous cell-cell interactions and can be used for antigen-specific immunotherapy....

Bone filler composition
12/18/14 - 20140370100 - A bone filler composition comprises a mixture of a curable calcium phosphate based bone filler which is formed from a liquid component and a calcium phosphate based powder component, and a formulation which comprises a bisphosphonate in particulate form. The particles of the bisphosphonate being embedded in particles of a...

2,2',6,6'-tetraisopropyl-4,4'-biphenol lipid microsphere preparations and preparation methods therefor
12/18/14 - 20140370101 - This invention relates to a 2,2′,6,6′-tetraisopropyl-4,4′-biphenol lipid microsphere preparation having 2,2′,6,6′-tetraisopropyl-4,4′-biphenol as its active ingredient and formed into said lipid microsphere preparation with common medically used injection-grade oil, emulsifier, and injection-grade water....

Method and composition for pharmaceutical product
12/18/14 - 20140370102 - This invention is directed to a composition comprising dry granulated tenofovir DF and emtricitabine, and a method for making same. Dry granulation was unexpectedly found to be important in preparing a tenofovir DF containing composition suitable for inclusion in a combination dosage form containing emtricitabine, efavirenz and tenofovir DF....

Non-immunogenic delivery vehicle for betta-, gamma-, and delta-tocopherols and methods of using and making same
12/18/14 - 20140370103 - This disclosure provides microparticles for the delivery of non-immunogenic compositions providing delivery of β-, γ- and/or δ-tocopherols....

Pharmaceutical formulations of flurbiprofen and glucosamin
12/11/14 - 20140363508 - The present invention relates to pharmaceutical formulations of flurbiprofen or a pharmaceutically acceptable salt thereof and glucosamine or salts thereof. Particularly, the present invention relates to a stable formulation of this combination having desired levels of dissolution rate and solubility which comprises at least one polymer having a low glass...

Compositions for the treatment of mucous membrane diseases
12/11/14 - 20140363509 - Composition comprising at least one active principle, at least one vehicle for said active principle and particles of porous silica, in which the active principle is contained in at least one pore of at least a first portion of such silica particles and in that vehicle, for use in the...

Pharmaceutical composition including pimobendan
12/11/14 - 20140363510 - A solid formulation includes pimobendan or a pharmaceutically acceptable salt thereof, which is homogenously dispersed with a polyvalent acid and a flavor suitable to animals....

Method of treating middle ear infections
12/11/14 - 20140363511 - Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane....

Pharmaceutical carrier and drug structure using the same
12/04/14 - 20140356433 - The present invention provides a pharmaceutical carrier and a drug structure using the carrier. The drug of the present invention comprises particular contents of chitosan, a negatively charged polymer, sodium tripolyphosphate, and an active ingredient, which combine with each other via electrostatic attraction. The drug structure has better release property...

Pharmaceutical formulation
12/04/14 - 20140356434 - Disclosed are aqueous pharmaceutical compositions which provide sustained released delivery of corticosteroid compounds. The pharmaceutical composition comprises an insoluble corticosteroid; a soluble corticosteroid; and at least one viscosity enhancing agent. Also provided are methods for using the pharmaceutical compositions in an epidural injection, intra-articular injection, intra-lesional injection, or an intra-ocular...

Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition
12/04/14 - 20140356435 - A method for manufacturing a drug-delivery composition includes providing at least a pharmaceutically active composition, providing a hydrophobic matrix; and mixing the hydrophobic matrix and the pharmaceutically active composition to form a paste-like or semi-solid drug-delivery composition....

Dermocosmetic compositions based on a synergistic combination of colloidal silver and deoxyribonucleic acid
12/04/14 - 20140356436 - The present invention relates to dermocosmetic compositions containing, as active ingredients, a synergistic combination of colloidal silver and deoxyribonucleic acid, characterized in that the colloidal silver is more particularly an aqueous solution of electro colloidal silver....

Corticosteroids for the treatment of joint pain
12/04/14 - 20140356437 - Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid...

Peripherally administered viscous formulations
12/04/14 - 20140356438 - Viscous formulations and methods of using such compositions, useful for intramuscular and intra-articular injection are provided to treat peripheral conditions. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10...

Novel hemostatic composition
11/27/14 - 20140348921 - the total quantity of water and humectant being comprised between 55 and 75% by weight relative to the total weight of the composition....

Process for producing a particulate composition comprising an hydrous crystalline 2-o-alpha-d-glucosyl-l-ascorbic acid
11/27/14 - 20140348922 - The invention provides a process for enabling the production of a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside that does not significantly cake even when the production yield of ascorbic acid 2-glucoside does not reach 35% by weight. The process for producing a particulate composition containing anhydrous crystalline ascorbic...

Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
11/27/14 - 20140348923 - A method for manufacturing a drug-delivery composition includes providing at least one pharmaceutically active compound, a dry powder comprising at least a polymer, and an aqueous solution. The dry powder, the pharmaceutically active compound and the aqueous solution are mixed to form a paste-like or semi-solid drug-delivery composition, wherein the...

Particles comprising single stranded rna and double stranded rna for immunomodulation
11/27/14 - 20140348924 - The present invention relates to chimeric particles comprising single stranded RNA (ssRNA), double stranded RNA (dsRNA) and at least one cationic agent, a pharmaceutical composition containing said particles and to a method of producing the same. The particles of the present invention are particularly useful as an immunostimulating medicament with...

Antioxidant ingredient with low calorie content, method for obtaining same and use thereof
11/27/14 - 20140348925 - The present invention relates to an antioxidant ingredient with low calorie content obtainable by a process that comprises the following steps: (a) selecting as raw material at least one fruit and/or plant material with high antioxidant content, greater than 6 g/100 g dry matter; (b) obtaining juice and pulp by...

Formulation and method for increasing oral bioavailability of drugs
11/27/14 - 20140348926 - The application discloses a formulation and method for increasing bioavailability of an orally administered drug....

Conditioning hair-cleaning agent
11/27/14 - 20140348927 - Cosmetic cleaning agents include in a cosmetically acceptable carrier a) at least one anionic surfactant, b) at least one cationic guar polymer, c) at least one silicone emulsion, in which the silicone particles have an average diameter of a maximum of 600 nm, and d) at least one wax. The...

Substituted n-aryl pyridinones
11/27/14 - 20140348928 - Disclosed herein are substituted N-Aryl pyridinone fibrotic inhibitors and/or collagen infiltration modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof....

Omega-3 fatty acid ester compositions
11/27/14 - 20140348929 - Described herein are compositions comprising at least one Omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one Omega-3 fatty acid...

Omega-3 fatty acid ester compositions
11/27/14 - 20140348930 - Described herein are compositions comprising at least one Omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one Omega-3 fatty acid...